<DOC>
	<DOCNO>NCT00706342</DOCNO>
	<brief_summary>The purpose study determine whether Fostamatinib Disodium safe effective treatment Adult Refractory Immune Thrombocytopenic Purpura ( ITP ) .</brief_summary>
	<brief_title>Pilot Study Fostamatinib Disodium/R935788 Treatment Adult Refractory Immune Thrombocytopenic Purpura ( ITP )</brief_title>
	<detailed_description>Patients chronic refractory ITP eligible 6- 12-week therapeutic trial . After 24 month treatment , patient continue demonstrate sustain response , investigator 's judgment , offer opportunity receive ongoing therapy .</detailed_description>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>Patients must willing able give write informed consent sign IRBapproved Informed Consent Form prior admission study . Patients may male female , age 18 75 . Men , sexually active , must agree use least one medically acceptable form birth control . Women childbearing potential must negative urine pregnancy test , agree use two independent method birth control , sexually active . Patients must diagnosis chronic refractory ITP least 3 month . Chronic refractory ITP define : 1 . Platelet count &lt; 30,000/mm3 consistently 3 month ( except transient nonsustained response various therapeutic regimen ) . There must least three separate platelet count ( 30,000/mm3 ) period , least one extend back three month prior patient entry study . 2 . The following condition exclude either history appropriate laboratory investigation : HIV infection ( see ) , lymphoproliferative disorder , myelodysplasia , SLE , druginduced alloimmune thrombocytopenia , dysglobulinemias . 3 . The patient must try least two typical regimen treatment ITP ( George et al. , Blood , 1996 ; Practice Guidelines , American Society Hematology ) . At least 50 % enrolled patient know refractory IVIg . Patients may may treat IVIg past . Subjects must test negative HIV , HBV , HCV standard serologic test within previous six month . Patients history presence substantial clinically significant respiratory , gastrointestinal , renal , hepatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , dermatological , disorder , Investigator 's opinion , could affect conduct study absorption , metabolism excretion study drug exclude . Specifically exclude lymphoma/chronic lymphocytic leukemia , hepatitis , HIV associate ITP . Patients history relevant drug hypersensitivity exclude . Patients history substance abuse , drug addiction alcoholism exclude . Patients follow laboratory abnormality : leukocyte count &lt; 2,500/mm3 , neutrophil count &lt; 1,800/mm3 , lymphocyte count &lt; 750/mm3 , Hgb &lt; 10 g/L , transaminase level ( ALT , AST ) &gt; 1.5xULN exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Adult Refractory Immune Thrombocytopenic Purpura ( ITP )</keyword>
</DOC>